Thus, the natural mutation of the BRAF gene is a hotspot target for scientists to study resistance to melanoma, and the inhibitor of mutated BRAF enzyme Vemurafenib and Dabrafenib have been marketed successively (Jordan and Kelly, 2012; Patel et al., 2020). The gene discussed is BRAF; the disease is melanoma.